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Abstract 
 
Neurons in the peripheral nervous system (PNS) have 
the capability to regenerate after injury or disease while 
central nervous system (CNS) neurons do not.  
Elucidation of the reasons for this difference in 
regenerative ability is crucial to developing treatments 
for sufferers of CNS disorders, injury, and stroke.  
Therefore, my lab investigates molecular mechanisms 
underlying neuronal repair, axonal guidance, and 
growth cone formation and collapse.  We discovered the 
Nogo protein and its inhibitory role in CNS repair.  The 
Nogo protein interacts with the Nogo-66 receptor (NgR), 
located on the axons of CNS neurons, to inhibit axonal 
sprouting after injury.  Blockage of this interaction by a 
competitive inhibitor allows limited CNS axon 
regeneration in vitro and in spinal cord injury model 
mice.  During normal development and repair, axonal 
pathfinding is mediated by the growth cone, which is 
guided by extra cellular cues that repel or attract the 
extending axon.  This extension is the result of 
continuous polymerization and depolymerization of the 
actin skeleton.  My lab works to elucidate the 
mechanism behind how these growth cones are guided, 
and we have uncovered a number of important steps in 
this pathway.  Understanding the inhibitory environment 
to CNS regeneration is essential to developing 
treatments for its disorders. 
	  
Introduction 
  
Central nervous system (CNS) injury, such as spinal cord 
injury (SCI), stroke, and neurodegenerative disease 
contribute heavily to the number of people suffering from 
disabilities in the United States.  In 2008, there were over 
250,000 Americans living with disabilities resulting from 
spinal cord damage, and that number will grow by 12,000 
cases each year1.  Over 5 million people suffered from 
stroke in 2005, and it is estimated that one stroke occurs in 
the United States every 40 seconds2. Impairment due to SCI 
typically stems from mechanical forces that damage spinal 
cord neurons while stroke leads to ischemia in brain tissue, 
resulting in cell death.  Neurodegenerative disease results in 
the progressive loss of neurons in the CNS, ultimately 
leading to symptoms characteristic of the disease3.  For 
example, Parkinson’s Disease (PD) results in loss of 
neurons in the substantia nigra, an area essential for 
voluntary movement3.  Thus, PD patients exhibit movement 
based symptoms that stem from CNS neuron loss.   In all 
cases, the neurons lost are irreplaceable.  Regeneration of 
lost CNS neurons is impaired by the endogenous inhibitors. 
Consequently, sufferers of CNS injury usually do not recover 
substantially from their disability.  Treatment typically 
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consists of physical therapy, which does result in minor 
improvement, but significant impairment still exists3. A to 
CNS repair found in the brain and spinal cord.  number of 
inhibitory factors contribute to the lack of regeneration in the 
CNS.  After injury to CNS neurons, astrocytes and glial cells 
are attracted to the site.  Astrocytes promote the formation of 
a glial scar, which inhibits regeneration of the neuron.  In 
addition, the myelin of the supporting oligodendrocytes 
contains proteins that interact with receptors on CNS 
neurons to inhibit growth3. 
Interestingly, the peripheral nervous system (PNS) 
faces no such obstacles to recovery following injury.  After 
damage to the PNS, macrophages rapidly and efficiently 
clear the resulting myelin debris, and genetic changes 
triggered in the cell lead to axonal extension through a 
structure called the growth cone.  Guided by extracellular 
cues released by supporting Schwann cells, the 
regenerating axon is guided into its correct position based on 
attraction or repulsion to the cues3. 
 My lab focuses on regenerative and 
developmental aspects of the nervous system.  We seek to 
explain how axons are guided into their proper position 
during development and repair through better understanding 
of growth cone biology.  A second aim is to elucidate the 
reasons for the differential regeneration ability between CNS 
and PNS neurons.  A better understanding of these 
processes is essential for improving current treatment of 
CNS disorders. 
 Our contributions to the field exist on two fronts.  
The exact component of CNS myelin that prevented 
regeneration was unidentified until 20004,5,6.  Along with two 
other labs, we first discovered the myelin associated protein 
Nogo, which has been found to contribute heavily to 
inhibition of CNS repair.  Further investigation into Nogo has 
revealed much about its inhibitory role in regeneration, 
including the receptor it interacts with and the structural 
features that mediate Nogo and receptor contact7.  Blocking 
this interaction has lead to improved function in SCI model 
mice8,9,10. 
Our second contribution results from the work 
conducted on the molecular mechanisms behind axonal 
guidance and growth cone sprouting.  Both intracellular and 
extracellular regulators of neuronal extension exist.  My lab 
characterized the functional mechanism of GAP-43, an 
intracellular regulator of axonal growth11.  We have also 
provided insight into the semaphorin family of extracellular 
growth regulators12. 
 
The Path To Nogo 
The difference in regeneration of CNS and PNS neurons has 
long puzzled the scientific community.  It was not until the 
late 1980s that the possible source of inhibition was 
discovered.  Martin Schwab’s lab discovered that 
oligodendrocytes and CNS myelin inhibit growth of CNS 
neurons13.  Further investigation proved the source of this 
inhibition stems from the presence of a 35-kd and 250-kD 
protein fraction (NI-35 & NI-250) that could be isolated from 
the myelin.  When damaged CNS neurons were exposed to 
myelin lacking these fractions, no inhibition was observed14.  
Schwab’s lab later went on to develop the IN-1 antibody, 
which binds to the NI-250 protein and its inhibitory effects15.  
Furthermore, treatment of SCI mice models with the IN-1 
antibody led to axonal regeneration16.  However, the exact 
identity of this protein and the gene that encodes it were still 
unknown. 
In 2000, our lab was one of three groups that 
identified the gene coding for NI-250.  The transcription  
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Figure 1:  Regeneration in the CNS vs. PNS Axonal regeneration is limited in the CNS as compared to the PNS.  Damage to the axon results in the 
deposition of myelin debris. In the PNS, this debris is cleared rapidly by macrophages.  However, no macrophages are present in the CNS to clear the 
debris, impeding neuronal repair.  In addition, CNS damage attracts astrocytes, which form a glial scar that prevents regeneration.  No astrocytes are 
present in the PNS to induce scarring.  CNS neuron regeneration is also hindered by inhibitory components in the myelin such as Nogo, MAG, and 
OMgp, all of which inhibit neuronal sprouting.  The PNS has no such inhibitory molecules, which allows for the extension of the growth cone and axonal 
sprouting.
	  
	  
product of the suspect gene believed to code for NI-250 was 
exposed to IN-1 antibody.  The IN-1 protein readily bound to 
NI-250. Additionally, we were able to isolate the cDNA 
coding for this protein and name it Nogo. The newly 
described protein is a member of the Reticulon family, and 
the gene codes for three forms of Nogo: Nogo-A, Nogo-B, 
and Nogo-C.  Nogo-A strongly inhibited chick dorsal root 
ganglion (DRG) outgrowth and was found to be expressed 
mainly in oligodendrocytes and CNS myelin4,5,6.  Thus, Nogo 
is a major contributor to the non-regenerative environment of 
the CNS.  However, the receptor that Nogo interacts with 
remained unidentified. 
  
Nogo Interacts with the Nogo-66 Receptor 
Nogo-A is a transmembrane protein that displays a 66 amino 
acid (aa) loop to the extracellular environment while the 
carboxyl region projects into the cytoplasmic space of the 
cell4,5,6.  The amino terminal domain of the protein also 
projects toward the extracellular space.  During the initial 
discovery of Nogo, the 66aa loop domain (Nogo-66) was 
found to be a potent inhibitor of axonal extension4.  This 
extracellular segment’s structure and function alluded to the 
idea that the Nogo protein interacts with a receptor of some 
kind.  Using an alkaline-phosphatase linked Nogo-66 protein, 
we established that Nogo strongly interacts with a protein 
found primarily in the brain.  This protein is characterized by 
a high number of leucine repeats, and its presence was 
 
 
required for sprouting inhibition8. Hence, this protein 
interacting with Nogo-66 was named the Nogo-66 Receptor 
(NgR).   
Determining the NgR protein’s location was the 
first step in elucidating the molecular basis for Nogo-66 and 
NgR interaction. If the NgR protein was found to be 
expressed on the outside of neurons, it would provide 
evidence that the Nogo protein, which is found on 
oligodendrocyte myelin, directly interacts with it.  
Immunostaining of spinal cord samples from chicks 
demonstrated that NgR is expressed mainly on the axons of 
these cells, which supports a model of Nogo-NgR interaction 
mediated by oligodendrocyte-neuron contact8.  Thus, it 
appears after injury that contact between the 
oligodendrocyte and injured neuron results in an interaction 
between NgR and Nogo to prevent axonal regeneration. 
The next step was to establish that the Nogo-66 
and NgR interaction indeed causes growth cone collapse.  
The NgR receptor was found to be crucial in preventing 
axonal sprouting through its interaction with Nogo.  Retinal 
ganglion cells from developing chick embryos were 
transfected with the gene coding for the NgR receptor.  
These neurons, now expressing the NgR receptor, were 
exposed to Nogo-66 protein.  Outgrowth of the retinal 
ganglion cells was severely limited upon exposure to Nogo-
66 due to growth cone collapse18.  This protein is GPI linked 
to the membrane of neurons, and cleavage of this GPI 
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linkage allows for axonal sprouting even in the presence of 
Nogo-6618.  Axonal damage leads to an increase in Nogo 
levels in oligodendrocyte myelin while NgR levels remain 
unaltered17.  The increase around the lesion site contributes 
to the inhibition of neuronal extension in this area18.  Upon 
axonal damage, Nogo interacts with the 66aa extracellular 
domain of Nogo the NgR receptor to inhibit axonal 
extension.  
 
NgR is Not Selective to Nogo-66 
In addition to Nogo, the NgR receptor interacts with a 
number of other myelin associated proteins.  In 1994, 
McKerracher et al found that myelin associated glycoprotein 
(MAG) inhibited neuronal outgrowth after injury19.  In 2002, 
Wang et al discovered a second molecule, OMgp, which 
inhibited axonal extension in a manner similar to MAG20.  In 
search for a commonality between these three inhibitory 
molecules, we assessed to what extent MAG and OMgp 
interact with the NgR receptor. 
 Using an AP binding assay, we found that MAG 
and OMgp bind to the NgR receptor and not the NgR2 or 
NgR3 receptors21.  In addition, the binding of MAG and 
OMgp requires the same leucine rich repeat region that is 
necessary for Nogo-66 binding.  This finding was somewhat 
surprising, as MAG and OMgp share no sequence homology 
to each other or to Nogo.  MAG and OMgp deficient mice 
both exhibit slightly increased axonal regeneration after SCI, 
indicating that these two myelin associated proteins are also 
major contributors to the lack of regeneration seen in CNS 
damaged neurons19,20. 
 The interaction of NgR with MAG, OMgp and 
Nogo is also dependent on a coreceptor, discovered by 
Wang et al in 2002.  As stated before, NgR is a GPI 
anchored protein.  Thus, it does not extend functional 
domains beneath the cell membrane and must function 
through a coreceptor to inhibit axonal outgrowth after binding 
its substrate.  Previous research demonstrated that p75 is 
required for inhibition of axonal repair by MAG, but that MAG 
does not interact directly with the receptor.  Using a p75 
knockout mice model, we found that signaling by NgR 
requires the presence of the p75 receptor22.  The discovery 
of this interaction provides yet another target to treat CNS 
impairment. 
 
Interruption of the Nogo/NgR Interaction Promotes Recovery 
after SCI in Mice 
We next began investigating how interrupting the Nogo/NgR 
receptor interaction could enhance spinal cord injury using a 
Nogo-66 antagonist peptide, NEP1-40.  The NEP1-40 
antagonist peptide does not trigger growth cone collapse of 
chick DRG neurons.  This peptide competitively binds to the 
NgR receptor and blocks the effect of Nogo.  Therefore, we 
used NEP1-40 to block Nogo in an in vitro and in vivo model 
system.  In vitro, chick DRG neurons grown on inhibitory 
CNS myelin treated with the antagonist peptide did not 
experience inhibited axonal sprouting8.  In vivo, SCI model 
mice that received intrathecal NEP1-40 exhibit increased 
CST sprouting through the site of the lesion, and perform 
statistically better in motor function tests as compared to 
untreated SCI mice8. 
The next step was to create lines of mice lacking 
Nogo to evaluate their ability to regenerate after SCI.  At the 
time, two other labs were pursuing the same goal, albeit 
each took a slightly different approach.  Our lab and Marc 
Tessier-Lavigne’s lab utilized a Nogo A/B deficient strain of 
young adult mice9,23.  Our colleague Martin Schwab utilized a 
Nogo knockout in which all three isoforms (Nogo-A, Nogo-B, 
and Nogo-C) were absent10. 
Contradictory results were obtained from the three 
labs.  Mine and Martin Schwab’s lab found that absence of 
either Nogo A or Nogo A/B increased sprouting of CST 
neurons across the lesion in SCI model mice9,10.  However, 
some additional differences were apparent.  The 
regeneration of CST fibers near the lesion shown by my lab 
was much more substantial than the regeneration shown by 
Dr. Schwab’s experiments.  Interestingly, the Nogo A -/- 
mice used by Dr. Schwab also exhibited elevated levels of 
Nogo-B.  It is possible that this increase in Nogo-B 
attenuates the lack of Nogo-A, and thus can explain the 
slightly decreased regenerative capacity as compared to the 
Nogo A/B -/- mice utilized by our lab.  To our surprise, Marc 
Tessier-Lavigne’s lab found no such regeneration using a 
similar mouse model as us23.  Their Nogo A/B -/- mice 
showed no evidence of increased regeneration.  Two 
explanations can possibly clear the confusion generated by 
these experiments.  Firstly, the genetic backgrounds of the 
mice utilized by all three labs were not identical.  Slight 
differences in gene expression could easily explain the 
differences in regeneration.  Secondly, the age of the mice 
used by the researchers was not controlled for across all 
three experiments.  Our lab demonstrated that older mice 
exhibited less pronounced regeneration after SCI as 
compared to younger mice9,10,23.  Thus, both age and genetic 
background can explain the differences seen by ours and Dr. 
Tessier-Lavigne’s lab. 
The NgR protein also proved to be instrumental in 
controlling regeneration after SCI.  We developed a function 
blocking NgR ectodomain protein, dubbed NgR(310)ecto-Fc.  
The spinal cord of rats was then damaged, followed by 
subsequent treatment of the NgR(310)ecto-Fc protein.  After 
treatment, CST fibers began extending across the lesion site 
and even began forming synaptic connections to their target 
neurons24.  The treated mice also regained substantial motor 
function, as demonstrated by significantly higher BBB scores 
compared to untreated mice.  Electrical activity of the 
neurons of treated mice more closely reflected normal 
neurons as well25.  Thus, the Nogo/NgR receptor interaction 
appears to be crucial in controlling recovery of CNS neurons 
after injury. 
 
Two Fronts of Nogo Inhibition 
We previously established that Nogo-66 has an inhibitory 
role on the outgrowth of extending neurons due to its 
interaction with NgR.  Although the Nogo protein clearly 
interacts with the NgR receptor and p75 coreceptor, the 
downstream pathway that ultimately results in growth cone 
collapse is not understood. The Rho family consists of a 
number of small GTPase proteins.  Previous research 
demonstrated that activation of Rho or Rho’s downstream 
effector, ROCK, results in diminished neuronal sprouting26.  
Growth cone collapse requires coordinated rearrangement of 
the actin cytoskeleton.  Rho GTPases have been found to be 
intimately involved in such actin transformations.  This 
knowledge led us to investigate the relationship between 
Rho and Nogo-66 inhibition.   
PC12 cells expressing the NgR receptor were 
treated with Nogo-66, and levels of GTP bound Rho were 
assessed.  Elevated levels of GTP bound Rho were found in 
response to Nogo-66 treatment.  In addition, blockade of the 
Rho pathway using the pyridine derivative Y-27632 resulted 
in axonal extension even in the presence of Nogo-6626.  
Thus, it appears that Nogo-66 activates the NgR receptor, 
which associates with the p75 receptor.  This NgR/p75 
complex then activates the Rho pathway, ultimately leading 
to a signaling cascade which results in collapse of the 
growth cone due to actin depolymerization. 
Interestingly, PC12 exposure to amino Nogo did 
not activate the Rho pathway.  Blockage of the Rho pathway 
using the Y-27632 followed by subsequent DRG neuron 
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Figure 2. Oligodendrocyte Myelin Components Inhibit Axonal Regeneration: Nogo-66, OMgp and MAG are myelin associated proteins that 
interact with the NgR receptor to inhibit axonal sprouting of neurons.  Binding of these myelin components to the NgR receptor recruits p75 and results 
in the subsequent activation of the Rho pathway.  Ultimately, axonal sprouting is inhibited.  Amino Nogo disrupts αv and α5 integrin to disrupt axonal 
sprouting and cell adhesion. 
 
 
exposure to amino Nogo still resulted in growth cone 
collapse26.   In addition, we found that amino Nogo does not 
interact with the NgR receptor to inhibit axonal growth7.  
These findings lead us to believe that the inhibitory effects of 
Nogo can be attributed to a second mechanism mediated by 
the amino terminus of the protein. Previous research 
demonstrates that amino Nogo inhibits cell adhesion of 
neurons and non-neuronal cells27.  It also inhibits neuronal 
outgrowth, and amino Nogo antibodies can attenuate this 
effect.  Integrins play a vital role in cell adhesion, and as a
result, we decided to evaluate the interaction between 
amino-Nogo and the integrin family of proteins.  COS-7 cells 
exposed to amino Nogo had decreased levels of 
phosphorylated focal adhesion kinase (FAK), indicating 
integrin activation was suppressed.  In addition, chick DRG 
neurons plated on fibronectin, an activator of integrin, and 
treated with amino Nogo failed to sprout axons27.  Moreover, 
we found amino Nogo to directly inhibit αv and α5 integrin 
subunits27.  Thus, Nogo inhibition of axonal sprouting occurs 
by two mechanisms: Nogo-66 interacts with the NgR 
receptor to activate the Rho pathway, and amino Nogo 
disrupts integrins to inhibit cell adhesion and axonal 
extension (figure 2). 
 
Nogo-66 Receptor is Involved in Alzheimer’s Disease 
Alzheimer’s disease is a neurodegenerative disorder 
characterized by the accumulation and aggregation of 
extracellular amyloid-beta (Aβ) protein28.  These Aβ plaques 
are thought to contribute to death of the neurons.  
Interestingly, abnormal axonal extension, which we have 
shown is mediated by the NgR receptor, is found to occur 
near Aβ accumulations.  Therefore, we investigated the role 
of the NgR receptor in Aβ deposition.  We assessed the 
accumulation of Aβ protein in APPswe/PSEN-1(ΔE9) 
Alzheimer’s model mice lacking the NgR receptor (-/-).  
Deletion of the NgR receptor resulted in increased Aβ plaque 
formation28.  In addition, treatment of APPswe/PSEN-1(ΔE9) 
mice with NgR(310)ecto-Fc protein lessened the formation of 
Aβ plaques.  Alzheimer’s model mice treated 
subcutaneously with NgR(310)ecto-Fc also decreased Aβ 
levels in cortical cells and improved spatial memory of the 
mice.  Their performance on a radial arm maze was 
significantly better than their untreated counterparts28.  Thus, 
NgR is clearly an intriguing target for treatment of 
Alzheimer’s disease, and further research is needed to fully 
elucidate its potential as a drug candidate. 
 
Potential Treatment of CNS Injury 
Current treatments for CNS injury are severely lacking.  
However, our research has uncovered a number of potential 
treatment avenues.  The Nogo and NgR pathway provide 
several targets alone.  Inhibition of Nogo-66 binding using 
the NEP1-40 antagonist peptide or blocking the NgR 
receptor using NgR(310)ecto-Fc protein both show promise 
in treating SCI in mice8,24.  The blockage of the NgR receptor 
is most likely to produce the best results, as MAG and OMgp 
also bind here to inhibit extension21.  Thus, simply blocking 
Nogo binding will not remove all obstacles to regeneration.  
In addition, the amino terminus of Nogo inhibits axonal 
regeneration by an integrin specific mechanism and would 
also have to be blocked to allow for unrestricted 
regeneration27.  A final method to enhance regeneration 
would be disruption of the Rho pathway.  Since binding of 
Nogo-66 leads to the activation of the Rho pathway and 
actin depolymerization, interruption of this activation could 
allow neuronal extension26.  One potential problem with this 
approach is that the Rho pathway is involved in more than 
just actin depolymerization, and thus side effects of this 
blockage could manifest in other abnormalities.   
 
	  	  
Intracellular and Extracellular Regulators of Growth Cone 
Structure 
In the PNS, no myeline associated proteins exist that inhibit 
growth cone formation after axonal trauma as in the CNS.  
Indeed, evidence has accumulated over the past 15 years 
that supports the presence of both intracellular and 
extracellular regulators of growth cone formation and 
guidance.  One such intracellular factor is the protein GAP-
4329.  This protein is found to be highly concentrated in the 
membrane of extending growth cones, but the structural 
basis for this localization during development and injury was 
unknown.  My lab identified the membrane targeting signal 
located on the N-terminal region of the protein30.  The 
function of GAP-43 also remained to be revealed.  We 
determined that the GAP-43 protein increases GTP binding 
to Go, a G-signaling protein that is found localized with GAP-
43 on extending axons31.  GAP-43 regulation of Go was a 
hypothesized mechanism of how GAP-43 controls neuronal 
plasticity.  G protein signaling is one known mechanism for 
changes in axonal growth31.  To test this, we injected GAP-
43 into oocytes of Xenopus laevis to determine its effect on 
G signaling.  We found that, upon injection, oocytes became 
up to 100 times more sensitive to G protein agonists11.  
Thus, it appears that GAP-43 modulates neuronal extension 
by increasing the sensitivity of G proteins to cellular 
signaling.  In crude terms, it acts as an amplifier of these 
signals, sensitizing the cell to the cues for growth cone 
structural change.   
 The regulation of GAP-43 is controlled by two 
post-translation modifications: palmitoylation and 
phosphorylation32.  Using GAP-43 mutants lacking regions 
critical for the protein’s amplification effect, we determined 
that palmitoylation of GAP-43 does not allow for amplification 
of signal transduction.  Unexpectedly, we determined that 
phosphorylation of serine-41is necessary for GAP-43 
activity32.  Thus, GAP-43 amplification of signal transduction 
occurs though sensitization of G-protein signaling and is 
controlled by both palmitoylation and phosphorylation of 
GAP-43. 
 Extracellular regulators of growth cone formation 
also exist.  One family of extracellular regulators is the 
semaphorin family.  This family includes the collapsin 
protein, discovered in 199333.  While collapsin is known to 
induce growth cone collapse, the mechanism behind this 
collapse was not well understood.  We first described the 
protein mediating collapse, CRMP-62, after discovering its 
cDNA in 199533.  We injected collapsin treated X. laevis 
oocytes with chick DRG membrane extracts.  Certain 
fractions of this membrane extract triggered a response by 
the oocytes to collapsin, and the cDNA of the protein in this 
fraction was cloned.  The isolated protein shared a 
homologous section with UNC-33, a protein required for 
axonal guidance in nematode CNS development33.  Thus, 
the collapsin interacts with CRMP-62 protein to induce 
growth cone collapse. 
 Actin depolymerization is characteristic of growth 
cone collapse.  The rho pathway has previously been 
implicated in restructuring of the actin network in 
neurons12,34.  Thus, we evaluated the interaction of the 
collapsin protein with rac1, a member of the rho small 
GTPase family.  We discovered that collapsin interacts with 
rac1 to cause growth cone collapse34.  In search of a 
receptor, we found that the collapsin protein binds to a 
plexin/neuropillin receptor35.  Similar to Nogo, collapsin 
collapses growth cones via two mechanisms.  The first is 
through interaction with the Rho signaling pathway to trigger 
destabilization of actin12.  The second is an increase in 
endocytosis of f-actin at the membrane of the growth cone.  
Typically, the amount of endocytosis and exocytosis at the 
growth cone membrane is relatively equal.  Upon collapsin 
treatment, endocytosis of growth cone membrane is 
enhanced, leading to further collapse of the extending 
axon36,37.  Thus, the collapsin protein causes collapse of 
growth cones through rearrangement of the actin 
cytoskeleton brought about by binding to the 
plexin/neuropillin receptor and subsequent Rho pathway 
activation.  It also enhances endocytosis of f-actin at the 
membrane of growth cones to inhibit axonal extension as 
well. 
 
Conclusion 
 
Regeneration of neurons in the CNS is limited in comparison  
to the PNS.  The molecular basis for these differences 
remained a mystery since the 1980s.  Our contribution to the 
field comes from the elucidation of the components involved 
in generating the restrictive regenerative atmosphere of the 
CNS.  The identification of Nogo and the NgR receptor 
revealed a major contributor to suppression of neuronal 
outgrowth.  In addition, we have determined that the NgR is 
involved in more than just Nogo binding, and also interacts 
with the inhibitory proteins MAG and OMgp to prevent 
axonal regrowth6,21.  In addition, we have shown that 
manipulation of the Nogo/NgR system has potential 
therapeutic applications in mice16,17.  In addition to CNS 
injury brought on by trauma, we have begun to investigate 
the role of the NgR receptor in Alzheimer’s28.  Thus, a wide 
spectrum of CNS disorders including trauma, stroke, and 
neurodegenerative disease are intimately linked to the Nogo 
and the NgR.  Treatment of these disorders requires further 
research into the pathways involved to develop safe, 
effective treatments for CNS maladies.  
 Axonal guidance is crucial for proper structure of 
the nervous system.  Both intracellular and extracellular 
regulators of axonal guidance exist.  The intracellular 
regulator GAP-43 was of unknown function in the early 
1990s.  My lab determined that the GAP-43 protein amplified 
G protein signal transduction, ultimately resulting in the 
restructuring of the growth cone11,30,31,32.  The semaphorins 
are a repulsive extracellular cue that collapses growth cones 
to repel them from inhospitable environments33,34.  The 
semaphorin collapsin was found to function through both a 
Rho mediated signaling pathway and an endocytic pathway 
to enhance growth cone collapse12.  Determination of the 
regulators of axonal guidance sheds insight into how the 
nervous system develops and obtains the highly ordered and 
complex network seen in the human body. 
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